PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Sodium valproate (NON childbearing potential) - Epilepsy

PAD Profile : Sodium valproate (NON childbearing potential) - Epilepsy

Keywords :
valproic acid
Brand Names Include :
Epilim, Epilim Chrono, Chronosphere, Episenta, Epival CR, Dyzantil

Traffic Light Status

Status 1 of 3.

Status :
Blue
Formulations :
  • Crushable tablets
  • Gastro-resistant tablets
  • Modified release tablets
  • Oral solution
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 3.

Status :
Blue
Formulations :
  • Capsules (slow release)
  • Granules (slow release)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 3 of 3.

Status :
Red
Formulations :
  • Injection
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
03 July 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands APC reviewed the Blue traffic light status for patients with epilepsy and WITHOUT child-bearing potential.

The Blue status remains with the expectation that treatment will be initiated and stabilised by a specialist and patients will receive a minimum of 1 month supply from the specialist before transfer of care.

No supplementary information sheet is required

Associated BNF Codes

04. Central Nervous System
04.08.01. Control of epilepsy
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More